Diagnosis and Predictive Molecular Analysis of Non–Small-Cell Lung Cancer in the Africa-Middle East Region: Challenges and Strategies for Improvement

Tomas Slavik, Fatima Asselah, Najla Fakhruddin, Ahmed El Khodary, Fairouz Torjman, Elia Anis, Martin Quinn, Azzam Khankan, Keith M. Kerr
2014 Clinical Lung Cancer  
has been a speaker or advisor for F. Hoffmann-La Roche Ltd, Lilly Oncology, AstraZeneca, Pfizer, and Merck Serono, for which he has received appropriate honoraria; Fairouz Torjman has received research funding from Dako Company; Martin Quinn is an employee of ACUMED®, who receive funding from Pfizer Inc. for medical writing services. Abstract Identification of tumour biomarkers provides information on prognosis and guides the implementation of appropriate treatment in patients with many
more » ... t types of cancer. In nonsmall-cell lung cancer (NSCLC), targeted treatment plans based on biomarker identification are already being utilised in the clinic. However, such predictive molecular testing is not currently a universally employed practice. This is particularly the case in developing countries where lung cancer is increasingly prevalent. In September 2012 and November 2013, a committee of 16 lung cancer experts from Africa and the Middle East met to discuss key issues related to diagnosis and biomarker testing in NSCLC and the implementation of personalised medicine in the region. The committee identified current challenges for effective diagnosis and predictive analysis in Africa and the Middle East. Moreover, strategies to encourage the implementation of biomarker testing were discussed. Ultimately, a practical approach for the effective diagnosis and predictive molecular testing of NSCLC in these regions was derived. Key issues and recommendations arising from the meetings are presented here. Abstract word count: 167 (journal limit: 250)
doi:10.1016/j.cllc.2014.06.005 pmid:25043210 fatcat:sl64ghjklbfe3lcibvfi4lwara